Overview of Profenid-Bi

Quick Facts

Property	Description
Active Ingredient	Ketoprofen
Form	Bi-layer tablet (Modified Release)
Pharmacological Class	Nonsteroidal Anti-Inflammatory Drug (NSAID)
General Purpose	Symptomatic relief of pain and inflammation
Origin	Synthetic (Propionic acid derivative)

What Type of Medicine is Profenid-Bi and What is its Composition?

Profenid-Bi is a synthetic prescription medication defined as a Nonsteroidal Anti-Inflammatory Drug (NSAID). Its sole active ingredient is Ketoprofen. This drug is classified chemically as a propionic acid derivative, placing it within a class of widely recognized analgesics.

The fundamental identity of the medicine lies in the compound Ketoprofen (C16H14O3), which is synthesized rather than being naturally derived. As a single-ingredient product, Profenid-Bi delivers only the therapeutic action of this derivative, functioning primarily to modulate key biological processes within the body. This composition is clinically recognized for managing the physical symptoms associated with acute inflammatory episodes.

The Dual Action of the Profenid-Bi Bi-Layer Tablet

The medication is supplied as an oral dosage form, specifically a specialized bi-layer tablet. This distinctive physical design is fundamental to the delivery mechanism and is a key differentiating feature of the Profenid-Bi brand.

The bi-layer tablet is engineered for modified release, meaning it combines two different types of release kinetics within one unit. One layer is formulated for immediate release of Ketoprofen to initiate the therapeutic effect quickly, while the second layer provides slow release of the remaining active ingredient over an extended period. This design is intended to sustain the therapeutic concentration of the propionic acid derivative in the bloodstream for effective, prolonged relief.

What is the General Purpose of Profenid-Bi?

The general purpose of Profenid-Bi is to provide symptomatic relief by targeting the underlying causes of discomfort and swelling. It achieves this by acting as an inhibitor of messengers like prostaglandins, which are responsible for triggering and escalating pain and inflammatory signals. By blocking the synthesis of these chemical triggers, the medication’s principal role is to mitigate the physical manifestations of inflammation, including swelling and redness, and to simultaneously reduce the sensation of pain.

What side effects are possible with Profenid-Bi?

Profenid-Bi: Possible Side Effects and Safety Information

Adverse reactions associated with Ketoprofen (Profenid-Bi) are formally classified by regulatory authorities based on body system and frequency of occurrence. The official safety profile is dominated by the risk of serious gastrointestinal and cardiovascular adverse events.

Key Adverse Reaction Scope

Category	Description
Serious Adverse Events	Risk of gastrointestinal bleeding, ulceration, and perforation, which can occur at any time without warning. Risk of cardiovascular thrombotic events (heart attack, stroke), which may increase with the duration of use.
Common Reactions	Officially classified as common are reactions such as dyspepsia, nausea, abdominal pain, headache, and dizziness.
Organ Systems Involved	Adverse reactions are documented across various System-Organ Classes, including Gastrointestinal, Nervous System, Cardiovascular, Skin and Subcutaneous Tissue, and Renal and Urinary Disorders.

Regulatory Safety Notes

Population-Specific Safety: Older adults are formally noted to be at a greater risk for serious gastrointestinal adverse events. The medicine is contraindicated during the third trimester of pregnancy due to documented risks of fetal cardiopulmonary toxicity. Safety statements also advise caution for patients with impaired renal or hepatic function.

Restrictions: The drug is contraindicated for the treatment of pain following Coronary Artery Bypass Graft (CABG) surgery. It is also restricted for patients who have previously experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs).

The official documentation categorizes events to provide a factual, label-based understanding of the medicine’s risk profile, which strictly adheres to government health authority findings.

Overdose and Emergency Response

Overdose and when to seek help

The following information is derived from official regulatory documentation regarding Ketoprofen overdose and required emergency actions.

Documented Overdose Manifestations

Overdose may present with documented signs across multiple physiological systems. Common manifestations listed in regulatory sources include gastrointestinal effects such as nausea, vomiting (sometimes bloody), and severe abdominal pain. Central nervous system effects such as drowsiness and dizziness are also documented. Severe or large overdoses have been officially associated with life-threatening outcomes, including gastrointestinal bleeding, ulceration, perforation, acute renal failure, seizures, and coma.

Mandated Emergency Action

Official prescribing information mandates immediate medical attention upon suspicion of an overdose or the onset of severe symptoms. Individuals must contact emergency services immediately. The elderly population is noted as being at a greater risk for serious gastrointestinal events following an NSAID overdose.

Treatment and Management

No specific antidote is known for Ketoprofen overdose. Therefore, treatment officially consists of symptomatic and supportive care. This management may involve procedures such as gastric decontamination (e.g., lavage) and the administration of activated charcoal. Hospital monitoring is required, and vital signs, along with blood and urine tests, and an ECG, are officially documented as necessary monitoring procedures.

Therapeutic Uses of Profenid-Bi

What Profenid-Bi Treats: Main Uses and Benefits

Profenid-Bi is primarily used to provide symptomatic relief by addressing pain, inflammation, and stiffness associated with various clinical conditions. The core benefit is in helping to ease symptoms related to inflammatory or irritative states, applicable within clinical settings that involve acute or disruptive symptom patterns. The medication is applied across domains where additional symptomatic support is needed, and contributes to easing the overall symptom load.

This medicine is relevant for managing symptoms that interfere with daily comfort, such as the pain of Rheumatoid Arthritis, Osteoarthritis, and Ankylosing Spondylitis. It is also applied in acute settings for discomfort following injuries like sprains and tendinitis, and for intense, episodic inflammatory flares, including acute gout attacks and primary dysmenorrhea. As a relevant part of symptomatic management, the intent is to support patients during episodes of heightened discomfort. The medication offers symptomatic relief that may help patients cope more steadily with symptom fluctuations.

Quick Fact: Symptomatic Support Domains

Symptom Domain	Use Case Relevance
Chronic Discomfort	Support for ongoing symptoms in conditions like Osteoarthritis.
Acute Swelling	Management of localized inflammation after trauma (sprains, strains).
Episodic Flares	Assistance with intense, temporary pain (Gout, Dysmenorrhea).

Regulatory References

NIH LiverTox overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Profenid-Bi?

Eligibility for Profenid-Bi (Ketoprofen) is strictly defined by regulatory guidelines, focusing on absolute contraindications and population-specific restrictions.

Absolute Contraindications

Use of this medicine is prohibited in several populations due to unacceptable risk, as documented in official labeling:

Patients with known hypersensitivity to Ketoprofen or in whom aspirin or other NSAIDs induce asthma, urticaria, or allergic reactions.
Patients requiring treatment for peri-operative pain following Coronary Artery Bypass Graft (CABG) surgery.
Pregnant women starting at 30 weeks gestation (the third trimester), due to the risk of fetal harm.

Population-Specific Restrictions

Population Group	Regulatory Eligibility Status
Pediatric Population (under 18 years)	Safety and efficacy have not been established for prescription use.
Adults (18 years and older)	Approved for use in conditions such as Rheumatoid Arthritis and Osteoarthritis.
Severe Organ Impairment	Patients with severe renal or hepatic dysfunction require significant reduction in the maximum total daily dose, and use is generally not recommended.
Lactation	Avoid use while breastfeeding, as drug distribution in breast milk is uncertain.

Eligibility is also restricted for patients with a history of GI ulcers or bleeding, Congestive Heart Failure, or Hypertension, who must use the medicine with extreme caution.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Profenid-Bi is structured around documented risks of additive pharmacodynamic effects and altered systemic exposure, as defined by regulatory authorities.

Interaction Restrictions

Type of Restriction	Interacting Agent or Condition
Contraindicated Use	Peri-operative pain management in the setting of Coronary Artery Bypass Graft (CABG) surgery.
Prohibited Co-administration	Ketorolac tromethamine.

Documented Interaction Patterns

Co-administration with other Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), anticoagulants, antiplatelet agents, and Oral Corticosteroids is associated with an additive pharmacodynamic risk, primarily increasing the likelihood of serious bleeding events. Selective Serotonin Reuptake Inhibitors (SSRIs) also increase bleeding risk.

Medicinal products for blood pressure and fluid retention, such as Diuretics, ACE Inhibitors, and Angiotensin Receptor Blockers (ARBs), may have their therapeutic effects diminished. This co-use creates an additive risk of acute renal failure.

In terms of systemic exposure, Probenecid is documented to increase Ketoprofen plasma levels by reducing its clearance. The combination of Ketoprofen with Lithium results in elevated plasma Lithium concentrations. High-dose Methotrexate also leads to elevated serum levels and increased toxicity. Alcohol consumption increases the risk of gastrointestinal bleeding. For the modified-release formulation, food does not alter total drug exposure but delays the time to peak concentration.

Mechanism of Action

Profenid-Bi's action is fundamentally driven by the pharmacodynamics of its active ingredient, Ketoprofen, which involves dual modulation of peripheral and central biological systems through enzyme inhibition and pathway influence. The mechanism functions across three core domains.

Targeted Inhibition of Prostaglandin Synthesis

This domain focuses on the reversible, non-selective inhibition of Cyclooxygenase (COX-1 and COX-2) enzymes within the arachidonic acid cascade. By blocking these critical enzymes, the drug restricts the formation of potent chemical mediators, primarily prostaglandins, leading to a foundational attenuation of localized biological responses linked to the synthesis of prostaglandins.

Dual Modulation of Nociceptive Signaling (Peripheral and Central)

The drug's mechanism extends beyond the site of mediator synthesis to influence nociceptive signaling. Peripherally, the reduction in prostaglandins decreases the sensitization of nociceptive nerve endings to other mediators. Centrally, Ketoprofen's activity includes modulation of spinal and suprasegmental pathways, affecting the central processing of nociceptive signals and altering activity within targeted neural pathways.

Functional Constraints of Non-Selective Action

Ketoprofen's non-selective binding creates a mechanistic trade-off, as inhibiting COX-1 also restricts the synthesis of cytoprotective prostaglandins required for constitutive physiological signaling, such as gastric mucosal integrity. This limitation is an inherent consequence of the molecular mechanism, altering the dynamics of other crucial regulatory processes.

Dosage and Administration Information

How Profenid-Bi is Used: Official Administration Guidelines

Administration Scope and Procedure

Profenid-Bi is intended solely for oral administration. The tablet is engineered with a modified-release dual-layer system; consequently, it must not be crushed, chewed, or divided under any circumstances, as this would compromise its intended release kinetics.

The typical regimen is a 100 mg to 200 mg dose administered Once Daily, with the maximum recommended dose for this formulation not exceeding 200 mg per day.

Context and Duration Protocol

For administration context, the tablet should be taken with sufficient fluids, preferably with food, to support gastric tolerance. This product adheres to the mandatory regulatory principle of using the lowest effective dose for the shortest duration possible required for symptomatic relief.

Population-Specific Instructions

Official guidelines mandate dose adjustments for specific groups. Individuals with impaired renal or hepatic function require a reduced initial dosage, and maintenance must utilize the minimal effective dose. Similarly, older adults are advised to begin treatment at a reduced dosage. The safety and efficacy for use in the pediatric population are not established. The procedural structure is therefore centered on a single, full-unit daily intake, subject to these maximum dose and duration constraints.

Recent Clinical Evidence

Research evidence / Overview of Studies for Profenid-Bi

Evidence for Symptomatic Relief in Chronic Inflammatory Conditions

Research involving the active ingredient in Profenid-Bi was studied for conditions characterized by fluctuating or episodic manifestations, such as Osteoarthritis (OA) and Rheumatoid Arthritis (RA). These investigations often involve Randomized Controlled Trials (RCTs), where the medicine is evaluated against a placebo or against other standard treatments.

Studies for these conditions primarily measure outcomes related to physical discomfort and research examines outcomes reflecting daily functioning or activity level, such as mobility and the ability to perform daily activities. The research base for the active ingredient in general includes evidence designated as High for these indications. The modified-release design was evaluated for its potential to maintain stable plasma concentrations over time.

Evidence for Acute Inflammatory Episodes

Research examined the active ingredient for conditions associated with acute or disruptive episodes and periods of heightened symptom activity. This evidence includes studies focusing on discomfort associated with Ankylosing Spondylitis (AS) symptoms, acute flares such as Gout attacks, pain from Primary Dysmenorrhea, and discomfort following Post-Traumatic Pain (like sprains).

These studies are generally short-term, with research focusing on episodes where symptoms become more noticeable. For Primary Dysmenorrhea, studies primarily used the immediate-release form of the active ingredient in research contexts involving fluctuating or unstable symptoms over a single cycle. The research highlights changes measured during the study period and documents symptom patterns.

Research Gaps and Areas of Uncertainty

Several limitations highlight areas where more research is needed. Follow-up durations were limited in many controlled trials, meaning there is limited information for long-term outcomes for patients using the medicine over many years. Data for certain subgroups remain insufficient, particularly in pediatric patients (under 18 years), where certainty remains low for this population. Research does not determine whether an individual will respond similarly, and results apply only to the populations studied in the official research record.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Profenid-Bi (FAQ)

Q: Why is Profenid-Bi called 'Bi'?

A: The name "Bi" is a reference to the tablet's bi-layer structure. Official product information explains that this unique design is engineered to provide two distinct release phases: one layer for immediate action and another for prolonged effect. This mechanism is intended to sustain the active ingredient's presence in the body.

Q: Is Profenid-Bi the same thing as regular ketoprofen?

A: Profenid-Bi contains the active ingredient Ketoprofen, but it is not the same as a regular, immediate-release ketoprofen tablet. Official documents note that it is formulated as a modified-release bi-layer tablet. This specific design allows the medicine to provide both an initial therapeutic effect and a sustained action over time.

Q: How long does the effect of Profenid-Bi usually last?

A: Profenid-Bi is formulated as a modified-release tablet intended for once-daily administration. The medicine is designed to sustain the therapeutic concentration of the active ingredient in the body for an extended period. This design is intended to provide sustained therapeutic concentrations.

Q: Can Profenid-Bi affect my blood pressure?

A: Regulatory documents state that Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) can potentially lead to new occurrences of high blood pressure (hypertension) or worsen existing hypertension. Regulatory documents indicate that monitoring of blood pressure may be necessary during treatment with this type of medicine.

Q: Is there a maximum number of days Profenid-Bi can be used?

A: Official administration guidelines emphasize using the lowest effective dose for the shortest duration necessary to achieve symptomatic relief. While a specific, universal maximum duration is not stated, this regulatory principle is applied to minimize the potential for long-term risks associated with NSAID use.

Q: Are there any common interactions with over-the-counter cold and flu medicines?

A: Many over-the-counter cold and flu medicines contain ingredients that can interact with Profenid-Bi, such as other NSAIDs or components that affect blood clotting. Official medical product information indicates that co-administration with other NSAIDs carries an increased additive risk of adverse events, and is therefore generally avoided.

Q: Is Profenid-Bi suitable for long-term use?

A: Regulatory documents highlight that the risk of serious side effects, including cardiovascular thrombotic events (heart attack, stroke) and gastrointestinal bleeding, may increase with the duration of use. For this reason, official guidance emphasizes that treatment should be for the shortest period possible required for relief.

Q: Is there a different way Profenid-Bi works compared to ibuprofen?

A: The active ingredient in Profenid-Bi works similarly to Ibuprofen, as both are non-selective NSAIDs. Official product information states that both medicines act by inhibiting cyclooxygenase (COX) enzymes. This inhibition is the mechanism responsible for reducing the sensation of pain and inflammation in the body.

Q: What is the difference between Profenid-Bi and a regular NSAID?

A: Profenid-Bi is distinguished by its modified-release bi-layer tablet design. This feature is detailed in product information and means the medicine provides a unique two-stage release of the active ingredient from a single dose. This differs from standard NSAID formulations, which typically release the entire dose immediately.

Q: What are the signs of a serious allergic reaction to Profenid-Bi?

A: Signs of a serious allergic-type reaction are documented in official safety information as including asthma, hives (urticaria), or swelling of the face, throat, or tongue (angioedema). These manifestations indicate hypersensitivity to the medicine.

Q: Can Profenid-Bi be used for pain after dental work?

A: The medicine is officially indicated for the treatment of pain associated with acute episodes of musculoskeletal conditions and post-traumatic pain. The specific use for dental pain is dependent on the full list of indications provided in the official product information.

Q: What is the legal classification of Profenid-Bi (prescription-only or OTC)?

A: Profenid-Bi is officially designated as a synthetic prescription medication, meaning it is only available by prescription (Rx Only) and is not an over-the-counter (OTC) medicine.

Q: Is Profenid-Bi known to cause skin rashes or sensitivity to the sun?

A: Regulatory information lists adverse reactions involving the skin, including reports of rash, hives (urticaria), and reactions to sunlight known as photosensitivity. This means the skin may become unusually sensitive to sun exposure while taking the medicine.

Q: Is there evidence that Profenid-Bi helps with chronic pain?

A: Research evidence primarily supports the use of the medicine for the symptomatic relief of pain and inflammation in chronic inflammatory conditions like Osteoarthritis (OA) and Rheumatoid Arthritis (RA). These conditions often involve chronic discomfort, and studies show benefit in managing the associated symptoms.

Q: What are the official approved uses for Profenid-Bi?

A: Official approved uses typically include conditions such as Rheumatoid Arthritis, Osteoarthritis, primary dysmenorrhea (painful periods), and the short-term management of acute pain. The specific list of indications is determined by the regulatory authority in each region.

Q: How quickly should I expect Profenid-Bi to start working?

A: The bi-layer design includes an immediate-release component that is specifically intended for rapid initial absorption. Official pharmacokinetic studies document the time it takes for the active ingredient to reach its maximum concentration in the body.

Q: Does Profenid-Bi cause weight gain or fluid retention?

A: The label classifies edema (fluid retention or swelling) as a potential adverse reaction of NSAIDs. Fluid retention is listed as a potential adverse reaction in official safety documentation.

Q: What happens if I miss a dose of Profenid-Bi?

A: The protocol for a missed dose in official product information generally states that the next dose should be taken at the regularly scheduled time, and a double dose should be avoided. This approach helps maintain the consistency of the prescribed regimen.

Q: Are there different strengths of Profenid-Bi available?

A: The product is supplied as a bi-layer tablet in specific strengths, such as 100 mg or 200 mg, depending on the regulatory region and the approved uses. The exact available strength will be indicated on the product packaging.

Q: Does Profenid-Bi contain aspirin or paracetamol (acetaminophen)?

A: Official product composition details confirm that Profenid-Bi is a single-ingredient product. Its only active substance is Ketoprofen. It does not contain Aspirin or Paracetamol (Acetaminophen).

Q: Can Profenid-Bi affect fertility?

A: Official regulatory texts note that the use of NSAIDs may impair female fertility and is a consideration for women who are planning to conceive. This effect is thought to be reversible upon stopping the medicine.

Q: What should I do if a side effect feels severe?

A: Official safety information regarding serious adverse events states that individuals should seek emergency medical attention or contact a health professional if signs of a serious reaction occur. These instructions are provided to ensure rapid management of serious health concerns.

Q: Does Profenid-Bi affect sleep patterns?

A: Adverse reaction tables in official product information typically list nervous system effects such as insomnia (difficulty sleeping) or somnolence (drowsiness) among reported events. Such effects are part of the documented safety profile.

Q: Can Profenid-Bi affect the results of lab tests?

A: Official regulatory documents may note that the medicine can interact with certain diagnostic procedures. Specifically, the medicine can lead to false-positive results on certain urine screening tests for other substances.

Q: Is it necessary to have regular check-ups while taking Profenid-Bi?

A: Regulatory text advises that patients on long-term NSAID therapy should have their blood count, blood pressure, renal function, and liver function monitored periodically. Monitoring is recommended to assess the potential impact of the medicine on these critical organ systems.

How should Profenid-Bi be stored and disposed of?

How to Store and Dispose of Profenid-Bi?

Profenid-Bi (ketoprofen modified-release tablets) must be stored under specific conditions to maintain product stability and integrity. The medicine requires storage at a temperature below 25 C.

Storage Requirements

The tablets must be stored in the original package to ensure protection from both light and moisture. It is mandatory that the medicine always be kept out of the sight and reach of children.

Disposal

Expired or unused Profenid-Bi must be managed responsibly according to official regulatory instructions. Do not throw away any medicines via wastewater or household waste. Instead, dispose of unused medicine according to local requirements for pharmaceutical waste.

Profenid-Bi